What is Artivion's market cap?

Artivion (AORT) has a market capitalization of $1.3B and trades on NYSE.

What is Artivion's revenue and profitability?

Artivion generated $458.7M in trailing twelve-month revenue with net income of $11.7M, representing a net margin of 2.5%. Gross margin stands at 64.6%, with free cash flow of -$1.1M. These figures are based on the Q1 2026 filing.

Who are Artivion's competitors?

Artivion's key competitors include Medtronic plc, Edwards Lifesciences, Abbott Laboratories, and others. These companies compete in similar markets and product categories.

Who does Artivion partner with?

Artivion's notable partners include Baxter International Inc., Endospan.

What subsidiaries does Artivion have?

Artivion's subsidiaries include JOTEC GmbH, On-X Life Technologies, Inc., Ascyrus Medical GmbH.

Where is Artivion headquartered?

Artivion is headquartered in United States of America and employs approximately 1,500 people. It has been publicly traded since 1993.

Artivion

AORT

Artivion is a medical technology company specializing in the manufacturing, processing, and distribution of medical devices and implantable human tissues.

Market cap

$1.27B-14.7%

Revenue$458.7M+17.6%

Net income$11.7M+155%

Free cash flow-$1.1M-110%

EPS (diluted)$0.24+148%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$116.3MBeat by $651.0K EPS$0.08Beat by $0.02

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$120.0M

EPS estimate$0.01

Financials

Q1 2026

Income statement

See full

Revenue$116.3M+17.5%

Gross profit$75.4M+18.7%

Operating income$5.8M+170%

Net income$1.4M+381%

EPS (diluted)$0.03+400%

Balance sheet

See full

Cash & equivalents$55.8M+47.9%

Total debt$258.2M-28.8%

Total equity$450.5M+53.1%

Total assets$883.2M+11.6%

Cash flow

See full

Operating cash flow$1.2M+107%

CapEx$8.0M+120%

Free cash flow-$6.8M+66.7%

Valuation & ratios

Valuation

See full

Market cap$1.27B-14.7%

Enterprise value$1.47B-12.7%

P/E108.4×—

P/S2.8×-0.9×

Profitability

See full

Gross margin64.6%+0.6pp

Operating margin8.2%+4.1pp

Net margin2.5%+1.5pp

Returns & leverage

See full

Return on equity3.1%+1.8pp

Debt / equity0.6×-0.7×

Current ratio3.9×-1.7×

Segments

By segment

See full

North America$58.7M+22.8%

EMEA$44.0M+18.7%

APAC$8.7M+5.8%

LATAM$5.0M-16.2%

By product

See full

Aortic stent grafts$44.4M+21.3%

On-X$26.0M+20.3%

Surgical sealants$18.8M+3.9%

Other$2.3M-9.0%

Competitors

By market cap

Abbott$182.00B-17.2%

Medtronic$107.81B-8.5%

Edwards Lifesciences$47.8B+3.8%

Merit Medical Systems$4.5B-9.1%

ITG

Integer Holdings$3.4B-10.9%

LeMaitre Vascular$2.3B+21.3%

Artivion$1.3B-14.0%

Humacyte$181.8M-52.6%

By revenue growth

Artivion+17.6%

Edwards Lifesciences+14.5%

LeMaitre Vascular+13.3%

Merit Medical Systems+11.1%

Medtronic+8.4%

Abbott+8.1%

ITG

Integer Holdings+6.3%

By net margin

LeMaitre Vascular24.35%+4.4pp

Edwards Lifesciences15.43%-57.5pp

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

Merit Medical Systems9.03%+0.2pp

ITG

Integer Holdings7.64%+3.2pp

Artivion2.55%+8.0pp

Profile

Artivion is a medical technology company specializing in the manufacturing, processing, and distribution of medical devices and implantable human tissues. The company focuses on providing innovative solutions for cardiac and vascular surgeons to treat patients suffering from complex aortic diseases, including aneurysms and dissections. Their value proposition centers on a comprehensive portfolio of life-restoring technologies ranging from mechanical heart valves to customized endovascular stent grafts.

Competitive position

Artivion is a leading provider of highly differentiated aortic arch stent grafts and mechanical heart valves, maintaining a specialized niche in complex aortic repair.

GeographiesUnited States, Germany, China, Brazil, Global

Customer segmentsHospitals, Surgical Specialists, Healthcare Systems

Business modelManufacturing, Direct Sales, Service Provider

SuppliersRaw material suppliers for synthetic grafts, Human tissue donors, Specialized chemical suppliers for glutaraldehyde and adhesives, Precision component manufacturers

CustomersCardiac and vascular surgeons, Hospital procurement departments, Group Purchasing Organizations (GPOs), Specialized heart centers

CountryUnited States of America

Listed1993

Employees1.5K

CEOJames Patrick Mackin

SectorHealthcare

IndustryMedical - Devices

Websiteartivion.com

FilingsSEC EDGAR

Ask your AI about Artivion.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Artivion's market cap?: Artivion (AORT) has a market capitalization of $1.3B and trades on NYSE.
What is Artivion's revenue and profitability?: Artivion generated $458.7M in trailing twelve-month revenue with net income of $11.7M, representing a net margin of 2.5%. Gross margin stands at 64.6%, with free cash flow of -$1.1M. These figures are based on the Q1 2026 filing.
Who are Artivion's competitors?: Artivion's key competitors include Medtronic plc, Edwards Lifesciences, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Who does Artivion partner with?: Artivion's notable partners include Baxter International Inc., Endospan.
What subsidiaries does Artivion have?: Artivion's subsidiaries include JOTEC GmbH, On-X Life Technologies, Inc., Ascyrus Medical GmbH.
Where is Artivion headquartered?: Artivion is headquartered in United States of America and employs approximately 1,500 people. It has been publicly traded since 1993.